Silo Pharma Proposes Reverse Stock Split, Board Elections at Annual Meeting

TL;DR

**SILO's proposed reverse stock split is a desperate move to prop up its share price; expect volatility and proceed with extreme caution.**

AI Summary

Silo Pharma, Inc. (SILO) is holding its 2025 Annual Meeting on October 24, 2025, where shareholders will vote on several critical proposals. Key among these is the election of four directors, the ratification of Salberg & Company, P.A. as the independent auditor for fiscal year ending December 31, 2025, and a significant proposal to amend the Company's Articles of Incorporation to effect a reverse stock split. This reverse stock split could range from 1-for-2 to 1-for-20, with the final ratio determined by the board within one year. Additionally, shareholders will vote on an amendment to the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan and an adjournment proposal. The Board unanimously recommends voting 'FOR' all proposals. As of the August 25, 2025 record date, there were 9,461,128 shares of common stock outstanding, each representing one vote.

Why It Matters

The proposed reverse stock split, ranging from 1-for-2 to 1-for-20, is a critical move for Silo Pharma, Inc. (SILO) that could significantly impact its stock price and market perception, potentially aiming for NASDAQ compliance or increased institutional investor appeal. For investors, this could mean fewer shares at a higher price per share, but it doesn't change the underlying company valuation. Employees and customers might see this as a strategic effort to stabilize the company's market position, while the broader market will watch to see if the split improves liquidity and investor confidence, especially in the competitive pharmaceutical sector.

Risk Assessment

Risk Level: high — The proposal for a reverse stock split at a ratio between 1-for-2 and 1-for-20 indicates significant concern about the company's stock price, potentially to meet exchange listing requirements. Historically, reverse stock splits are often viewed negatively by the market and can lead to further stock price declines, as evidenced by the broad range of the proposed split ratio, giving the board wide discretion and uncertainty for investors.

Analyst Insight

Investors should carefully evaluate the implications of the proposed reverse stock split, as it often signals underlying financial challenges. Consider reducing exposure or hedging positions given the high risk and potential for further dilution or price depreciation post-split. Monitor the outcome of the vote and the board's chosen ratio closely.

Key Numbers

• 9,461,128 — Shares of common stock outstanding (As of the August 25, 2025 record date, each share represents one vote.)
• 1-for-2 to 1-for-20 — Reverse Stock Split Ratio (The proposed range for the reverse stock split, with the final ratio to be selected by the board.)
• 4 — Directors to be elected (Number of members to be elected to the Board of Directors for a one-year term.)
• December 31, 2025 — Fiscal year end (For which Salberg & Company, P.A. is proposed as the independent registered public accounting firm.)
• 3,153,710 — Shares for quorum (One-third of the 9,461,128 shares outstanding required to constitute a quorum at the 2025 Annual Meeting.)

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant and subject of the DEF 14A filing
• Salberg & Company, P.A. (company) — Independent registered public accounting firm for fiscal year ending December 31, 2025
• Eric Weisblum (person) — Chairman of the Board of Directors and Chief Executive Officer
• SEC (regulator) — U.S. Securities and Exchange Commission
• West Coast Stock Transfer, Inc. (company) — Transfer agent for Silo Pharma, Inc.
• Campaign Management (company) — Strategic Stockholder Advisor and Proxy Solicitation Agent
• 9,461,128 (dollar_amount) — Shares of common stock outstanding as of the Record Date
• August 25, 2025 (date) — Record date for the 2025 Annual Meeting
• October 24, 2025 (date) — Date of the 2025 Annual Meeting
• 1-for-2 to 1-for-20 (dollar_amount) — Range for the proposed reverse stock split ratio

FAQ

Risk Factors

• Reverse Stock Split Dilution [medium — financial]: The proposed reverse stock split, ranging from 1-for-2 to 1-for-20, is intended to increase the per-share market price of the Company's common stock. However, a reverse stock split can sometimes be perceived negatively by the market, potentially leading to a decrease in stock price or increased volatility. The board has discretion to set the final ratio within one year, creating uncertainty for shareholders regarding the immediate impact on their holdings.
• Dependence on Board Decisions [medium — operational]: Key strategic decisions, such as the final ratio of the reverse stock split, are left to the discretion of the board of directors within a one-year period. This concentration of decision-making power without immediate shareholder input on the specific ratio could lead to outcomes not aligned with all shareholder expectations.
• Compliance with Exchange Listing Standards [high — regulatory]: While not explicitly stated as a risk, reverse stock splits are often undertaken to meet minimum bid price requirements for stock exchange listings. Failure to maintain compliance could lead to delisting, which would significantly impact liquidity and shareholder value. The need for a reverse split suggests potential prior challenges in this area.

Industry Context

Silo Pharma operates within the biotechnology and pharmaceutical sector, a highly competitive and research-intensive industry. Companies in this space often face significant challenges related to drug development, clinical trials, regulatory approvals, and market access. The industry is characterized by high R&D costs, long development cycles, and the potential for substantial returns upon successful product commercialization, but also high failure rates.

Regulatory Implications

The proposed reverse stock split may be driven by a need to comply with stock exchange listing requirements, such as maintaining a minimum share price. Failure to meet these requirements could lead to delisting, impacting liquidity and investor confidence. The company must also navigate ongoing FDA regulations and compliance standards for any pharmaceutical products it develops.

What Investors Should Do

1. Review the proposed reverse stock split details carefully.
2. Vote on director nominees.
3. Consider the ratification of the independent auditor.
4. Ensure your vote contributes to quorum.

Key Dates

• 2025-10-24: 2025 Annual Meeting of Shareholders — Shareholders will vote on critical proposals including director elections, auditor ratification, a reverse stock split, and equity plan amendments. The outcome of these votes will shape the company's governance and financial structure.
• 2025-08-25: Record Date for 2025 Annual Meeting — Establishes the list of shareholders entitled to vote at the annual meeting. 9,461,128 shares of common stock were outstanding on this date.
• 2025-09-05: Mailing of Notice of Internet Availability of Proxy Materials — Marks the official start of the proxy solicitation period, providing shareholders access to voting materials and information about the annual meeting.
• 2025-12-31: Fiscal Year End — The fiscal year for which Salberg & Company, P.A. is proposed as the independent auditor.

Glossary

DEF 14A

A Schedule 14A filing (DEF 14A) is a proxy statement filed with the SEC by a company when it is soliciting shareholder votes for its annual meeting or other matters. (This document is the proxy statement for Silo Pharma's 2025 Annual Meeting, detailing the proposals and providing information for shareholders to make informed voting decisions.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (Silo Pharma is proposing a reverse stock split to potentially increase its stock price, which is a key proposal shareholders will vote on.)

Articles of Incorporation

The foundational legal document of a corporation, filed with the state, that outlines the basic structure and purpose of the company. (An amendment to the Articles of Incorporation is required to implement the proposed reverse stock split.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (August 25, 2025, is the record date for Silo Pharma's 2025 Annual Meeting, with 9,461,128 shares outstanding.)

Quorum

The minimum number of shareholders or shares required to be present at a meeting for business to be legally transacted. (One-third of the outstanding shares (3,153,710) are required to constitute a quorum for Silo Pharma's 2025 Annual Meeting.)

Proxy

A document or authorization that allows a shareholder to delegate their voting rights to another person (the proxy) to vote on their behalf. (Shareholders are urged to complete and return a proxy card to ensure their vote is counted, even if they cannot attend the meeting.)

Year-Over-Year Comparison

This filing is a proxy statement for the 2025 Annual Meeting, focusing on upcoming shareholder votes. It does not contain comparative financial data from a previous year's proxy statement. However, the reference to the 2024 Annual Report on Form 10-K suggests that shareholders can access historical financial performance separately. The key proposals, particularly the reverse stock split, indicate a strategic move by the company, potentially in response to market conditions or listing requirements not detailed in this proxy statement.

Key Financial Figures

• $8,000 — nnual Meeting at an approximate cost of $8,000, plus reimbursement of expenses. If you

Filing Documents

• ea0255705-def14a_silo.htm (DEF 14A) — 434KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 1049KB
• image_003.jpg (GRAPHIC) — 375KB
• 0001213900-25-085119.txt ( ) — 4296KB
• silo-20250905.xsd (EX-101.SCH) — 10KB
• silo-20250905_def.xml (EX-101.DEF) — 2KB
• silo-20250905_lab.xml (EX-101.LAB) — 33KB
• ea0255705-def14a_silo_htm.xml (XML) — 24KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 SILO PHARMA, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 SILO PHARMA, INC. 677 N Washington Boulevard Sarasota, Florida 34236 NOTICE OF 2025 ANNUAL MEETING OF SHAREHOLDERS To Be Held on October 24, 2025 Dear Stockholders: The 2025 Annual Meeting of Stockholders (the " 2025 Annual Meeting " or, " Annual Meeting ") of Silo Pharma, Inc., a Nevada corporation (the "Company," "we," "us," or "our"), will be held on October 24 2025, at 11:00 a.m. Eastern Time at our office located at 677 N Washington Boulevard, Sarasota, Florida 34236. At the 2025 Annual Meeting, the holders of our outstanding common stock will act on the following matters: 1. To elect four (4) members to our Board of Directors to serve for a one-year term to expire at the 2026 annual meeting of shareholders; 2. To ratify the appointment of Salberg & Company, P.A. (" Salberg ") as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 3. To approve an amendment to the Company's Articles of Incorporation to effect a reverse stock split of the Company's outstanding common stock, at a ratio within the range of 1-for-2 to 1-for-20 (the " Reverse Stock Split "), with the final ratio to be selected by our board of directors in its discretion at any time, if at all, within one year of the date of the 2025 Annual Meeting without further approval or authorization of our shareholders (the " Reverse Stock Split Proposal "); 4. To approve the First Amendment to the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan (the " Equity Plan Amendment Proposal "); 5. To authorize the adjournment of the 2025 Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals (the " Adjournment Proposal "); and 6. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. Our Board unanimously recommends that you vote " FOR " the election of our Board's director nominees (Proposal 1); " FOR " the ratification of the appointment of Salberg as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (Proposal 2); " FOR " the Reverse Split Proposal (Proposal 3); " FOR " the Equity Plan Amendment Proposal (Proposal 4); and " FOR " the approval of the Adjournment Proposal (Proposal 5). Instead of mailing a printed copy of our proxy materials to all of our stockholders, we provide access to these materials via the Internet. This reduces the amount of paper necessary to produce these materials as well as the costs associated with mailing these materials to all stockholders. Accordingly, on or about September 5, 2025, we will begin mailing a Notice of Internet Availability of Proxy Materials (the " Notice ") to all stockholders of record on our books at the close of business on August 25, 2025, the record date for the 2025 Annual Meeting, and will post our proxy materials on the website referenced in the Notice. As more fully described in the Notice, stockholders may choose to access our proxy materials on the website referred to in the Notice or may request to receive a printed set of our proxy materials. In addition, the Notice and website provide information regarding how you may request to receive proxy materials in printed form by mail, or electronically by email, on an ongoing basis. Our Board of Directors has fixed August 25, 2025 as the record date (the " Record Date ") for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting and at any adjournment or postponement of the meeting. If you are a stockholder of record, you may vote in one of the following ways: Stockholders of Record For your convenience, record holders of our common stock have four methods of voting: 1. Vote by Internet. The website address for Internet voting is on your vote instruction form; 2. Vote by mail . Mark, date, sign and promptly mail the enclosed proxy card; 3. Vote by fax . Mark, date, sign and promptly

View Full Filing

View this DEF 14A filing on SEC EDGAR